DN
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Antifungal treatment duration in hematology patients with invasive mold infections : a real-life update | Open forum infectious diseases |  | 2024 | 21 | 7 | ||
| Isavuconazole for the Treatment of Fungal Infections : A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS) | Open forum infectious diseases | | 2024 | 10 | 11 | ||
| Do infectious diseases after kidney retransplantation differ from those after first kidney transplantation ? | Open forum infectious diseases | | 2024 | 49 | 13 | ||
| Pitfalls in Valganciclovir Prophylaxis Dose Adjustment Based on Renal Function in Kidney Transplant Recipients | Transplant international | | 2024 | 51 | 17 | ||
| Frequency and impact on renal transplant outcomes of urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species | Frontiers in medicine | | 2024 | 38 | 10 | ||
| Pre-engraftment bacteremia after allogeneic hematopoietic cell transplantation without primary fluoroquinolone antibacterial prophylaxis | Transplant infectious disease | | 2024 | 7 | 8 | ||
| Epidemiology, outcomes and risk factors for recurrence of Clostridioides difficile infections following allogeneic hematopoietic cell transplantation : a longitudinal retrospective multicenter study | Bone marrow transplantation | | 2024 | 30 | 7 | ||
| Routine infectious disease consultation prior to an allogeneic hematopoietic cell transplant | Open forum infectious diseases | | 2023 | 22 | 10 | ||
| Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities : A Multi-Center Retrospective Study | Journal of Fungi | | 2023 | 52 | 24 | ||
| Vaccine-preventable infections among solid organ transplant recipients in Switzerland | JAMA network open | | 2023 | 69 | 11 | ||
| Revisiting cytomegalovirus serology in allogeneic hematopoietic cell transplant recipients | Clinical infectious diseases | | 2023 | 53 | 17 | ||
| Antifungal prophylaxis and pre-emptive therapy : when and how ? | Molecular aspects of medicine | | 2023 | 47 | 12 | ||
| Duration of antifungal treatment in mold infection : when is enough ? | Current opinion in infectious diseases | | 2023 | 42 | 0 | ||
| The present and future of blood virome in allogeneic hematopoietic cell transplant recipients | Current opinion in infectious diseases | | 2023 | 54 | 2 | ||
| Bloodstream infections in allogeneic haematopoietic cell recipients from the swiss transplant cohort study: trends of causative pathogens and resistance rates | Bone marrow transplantation | | 2023 | 92 | 31 | ||
| American Society for Transplantation and Cellular Therapy Series, #6 : Management of Invasive Candidiasis in Hematopoietic Cell Transplantation Recipients | Transplantation and cellular therapy | | 2023 | 42 | 21 | ||
| CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients | Open forum infectious diseases | | 2023 | 59 | 10 | ||
| Immunogenicity of High-Dose vs. MF59-adjuvanted vs. Standard Influenza Vaccine in Solid Organ Transplant Recipients : The STOP-FLU trial | Clinical infectious diseases | | 2023 | 52 | 12 | ||
| Immune monitoring-guided vs fixed duration of antiviral prophylaxis against cytomegalovirus in solid-organ transplant recipients. A Multicenter, Randomized Clinical Trial | Clinical infectious diseases | | 2023 | 72 | 21 | ||
| Invasive Aspergillosis and the Impact of Azole-resistance | Current fungal infection reports | | 2023 | 42 | 7 | ||
| Longitudinal Detection of Twenty DNA and RNA Viruses in Allogeneic Hematopoietic Stem Cell Transplant Recipients Plasma | Viruses | | 2023 | 97 | 52 | ||
| Bacteremia During the First Year After Solid Organ Transplantation : An Epidemiological Update | Open forum infectious diseases | | 2023 | 70 | 17 | ||
| Salvage Treatment of Refractory HSV Oral Lesions with Pritelivir in Allogeneic Hematopoietic Cell Transplant Recipients | Antimicrobial agents and chemotherapy | | 2023 | 52 | 70 | ||
| Hepatitis E Virus Infection Epidemiology in Recipients of Allogeneic Hematopoietic Cell Transplant | Open forum infectious diseases | | 2023 | 24 | 13 | ||
| Nouveautés dans la prise en charge de l’infection à cytomégalovirus chez les patients transplantés | Revue médicale suisse | | 2023 | 48 | 2 | ||
| Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress? | Open forum infectious diseases | | 2022 | 219 | 109 | ||
| Central nervous system infections in solid organ transplant recipients: Results from the Swiss Transplant Cohort Study | The Journal of infection | | 2022 | 182 | 93 | ||
| Atypical pulmonary phaeohyphomycosis due to Aureobasidium spp. - case report and brief literature review | Swiss medical weekly | | 2022 | 136 | 28 | ||
| Distribution of Aspergillus Species and Prevalence of Azole Resistance in Respiratory Samples From Swiss Tertiary Care Hospitals | Open forum infectious diseases | | 2022 | 174 | 59 | ||
| Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients | Antimicrobial agents and chemotherapy | | 2022 | 41 | 51 | ||
| Frequency and causes of antifungal treatment changes in allogeneic haematopoïetic cell transplant recipients with invasive mould infections | Mycoses | | 2022 | 213 | 99 | ||
| Impact of different urinary tract infection phenotypes within the first year post-transplant on renal allograft outcomes | American journal of transplantation | | 2022 | 138 | 58 | ||
| Letermovir for cytomegalovirus primary prophylaxis in a multiple abdominal/small bowel transplant recipient | Clinical transplantation |  | 2022 | 192 | 0 | ||
| Epidemiology and outcomes of bone and joint infections in solid organ transplant recipients | American journal of transplantation | | 2022 | 153 | 45 | ||
| T cell receptor sequencing reveals reduced clonal breadth of T-cell responses against SARS-CoV-2 after natural infection and vaccination in allogeneic hematopoietic stem cell transplant recipients | Annals of oncology | | 2022 | 97 | 29 | ||
| When and how do we stop antifungal treatment for an invasive mould infection in allogeneic haematopoietic cell transplant recipients? | Mycoses | | 2022 | 57 | 13 | ||
| Surgical site infections after simultaneous pancreas kidney and pancreas transplantation in the Swiss Transplant Cohort Study | Journal of hospital infection | | 2022 | 162 | 54 | ||
| Epidemiology and outcomes of medically attended and microbiologically confirmed bacterial foodborne infections in solid organ transplant recipients | American journal of transplantation | | 2022 | 147 | 57 | ||
| Screening for Parasitic Infection and Tuberculosis in Immunosuppressed and Pre-Immunosuppressed Patients: An Observational Study | Tropical medicine and infectious disease | | 2021 | 182 | 78 | ||
| COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it? | Clinical microbiology and infection | | 2021 | 150 | 60 | ||
| Progress and current challenges in the management of invasive fungal infections in hematologic malignancy patients and allogeneic hematopoietic cell transplant recipients | | 2021 | 228 | 241 | |||
| Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study | Vaccines | | 2021 | 159 | 140 | ||
| Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study | American journal of transplantation | | 2021 | 201 | 81 | ||
| Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients | Immunity, inflammation and disease | | 2021 | 252 | 62 | ||
| Temporal trends, risk factors and outcomes of infections due to extended-spectrum β-lactamase producing Enterobacterales in Swiss solid organ transplant recipients between 2012 and 2018 | Antimicrobial resistance and infection control | | 2021 | 245 | 53 | ||
| Burden, epidemiology, and outcomes of microbiologically confirmed respiratory viral infections in solid organ transplant recipients: a nationwide, multi-season prospective cohort study | American journal of transplantation | | 2021 | 96 | 60 | ||
| Clinical considerations of isavuconazole administration in high-risk hematological patients: a single-center 5-year experience | Mycopathologia | | 2021 | 181 | 97 | ||
| Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients | Medical mycology | | 2021 | 239 | 1 | ||
| Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response | BMC infectious diseases | | 2021 | 99 | 70 | ||
| Differences between infectious disease events in first liver transplant versus retransplantation in the Swiss Transplant Cohort Study | Liver transplantation | | 2021 | 101 | 0 | ||
| Editorial: Transplant infectious disease landscape in the COVID19-Era | Current opinion in infectious diseases | | 2021 | 143 | 0 | ||
| The EHA research roadmap: infections in hematology | HemaSphere | | 2021 | 139 | 53 | ||
| Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir | Antimicrobial agents and chemotherapy | | 2021 | 179 | 242 | ||
| Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey | Open forum infectious diseases | | 2021 | 35 | 36 | ||
| Real-life considerations on antifungal treatment combinations for the management of invasive mold infections after allogeneic cell transplantation | Journal of Fungi | | 2021 | 139 | 80 | ||
| Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study | The journal of antimicrobial chemotherapy | | 2021 | 152 | 0 | ||
| Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients | Medical mycology | | 2021 | 122 | 0 | ||
| Invasive aspergillosis due to Aspergillus section Usti: a multicenter retrospective study | Clinical Infectious Diseases | | 2020 | 176 | 438 | ||
| Risk factors for candidemia: a prospective matched case-control study | Critical Care | | 2020 | 275 | 92 | ||
| Response to "Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study" | Blood advances | | 2020 | 137 | 30 | ||
| Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland | Infection | | 2020 | 183 | 81 | ||
| First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study | American Journal of Transplantation | | 2020 | 227 | 75 | ||
| Intracellular Pathogen in the Cerebrospinal Fluid of an Allogeneic Hematopoietic Cell Transplant Recipient With Graft-Versus-Host Disease and Brain Lesions | Clinical infectious diseases | | 2020 | 198 | 0 | ||
| Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm | Medical Mycology | | 2020 | 157 | 215 | ||
| Optimal treatment duration of pseudomonas aeruginosa infections in allogeneic hematopoietic cell transplant recipients | Open Forum Infectious Diseases | | 2020 | 409 | 99 | ||
| First case of Cryptococcus gattii multilobar pneumonia in Switzerland and associated challenges | Swiss Medical Weekly | | 2020 | 333 | 114 | ||
| Combination treatment with letermovir and ganciclovir for maintenance therapy of multidrug-resistant CMV infection in a liver transplant recipient | Transplantation | | 2020 | 294 | 1 | ||
| Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study | Transplant Infectious Disease | | 2020 | 329 | 2 | ||
| Prophylaxie antimicrobienne et approches thérapeutiques empiriques et préemptives pour la prévention des infections chez les receveurs de greffe allogénique de cellules hématopoïétiques | | 2020 | 359 | 148 | |||
| Infectiologie sur mesure - 1. Immunogénétique des maladies infectieuses : premiers pas | Revue médicale suisse | | 2019 | 194 | 1 | ||
| National point prevalence survey on healthcare-associated infections in acute care hospitals, Switzerland, 2017 | Euro Surveillance | | 2019 | 303 | 111 | ||
| Antimicrobial prophylaxis and preemptive approaches for the prevention of infections in the stem cell transplant recipient, with analogies to the hematologic malignancy patient | Infectious disease clinics of North America | | 2019 | 116 | 109 | ||
| Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in the Swiss Transplant Cohort Study | Transplant Infectious Disease | | 2018 | 428 | 0 | ||
| Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy | Haematologica | | 2018 | 199 | 111 | ||
| Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS) | Clinical Microbiology and Infection | | 2018 | 226 | 166 | ||
| Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients | Transplant Infectious Disease | | 2018 | 226 | 76 | ||
| Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study | Transplant Infectious Disease | | 2018 | 411 | 0 | ||
| Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort | Transplant Infectious Disease | | 2018 | 336 | 1 | ||
| First case of Candida auris in Switzerland: discussion about preventive strategies | Swiss Medical Weekly | | 2018 | 435 | 174 |
